TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8360063

Group type: EXPERIMENTAL
Intervention: Home exercise program using transtelephonic exercise monitoring (TEM) for 12 weeks, training 3 days per week for a maximum of 35 minutes at 75% of maximum heart rate reserve.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hospital-based exercise program for 12 weeks, training 3 days per week for a maximum of 35 minutes at 75% of maximum heart rate reserve.
Number of subjects: 20
Study: 3312625

Group type: EXPERIMENTAL
Intervention: 9 mg/kg methylprednisolone (steroid-treated)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 31547713

Group type: EXPERIMENTAL
Intervention: Conventional immunotherapy in children
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Cluster immunotherapy in children
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Conventional immunotherapy in adults
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Cluster immunotherapy in adults
Number of subjects: 149

Group type: COMPARATOR
Intervention: All groups (conventional and cluster)
Number of subjects: 149
Study: 29496605

Group type: EXPERIMENTAL
Intervention: RVA pacing
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: RVS pacing
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: LV-CS pacing
Number of subjects: 63

Group type: COMPARATOR
Intervention: RVA-ICD
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Right ventricular leads
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: LV-CS leads
Number of subjects: 63
Study: 27647770

Group type: EXPERIMENTAL
Intervention: Ormeloxifene (60 mg twice per week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combined Oral Contraceptive (ethinyl estradiol 30 μg with desogestrel 150 μg on days 1-21 for 6 months)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 24188122

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (SLBs)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional brackets (CBs)
Number of subjects: 46
Study: 23059433

Group type: EXPERIMENTAL
Intervention: Active reflexology treatment to areas of the feet corresponding to the heart
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control reflexology treatment to other areas of the feet
Number of subjects: 16
Study: 20212250

Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel with sorafenib (arm A)
Number of subjects: 926

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel with placebo (arm B)
Number of subjects: 926
Study: 18493254

Group type: EXPERIMENTAL
Intervention: Computerised anaesthesia delivery system (Wand)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: High dental anxiety
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Low dental anxiety
Number of subjects: 147
Study: 15747811

Group type: EXPERIMENTAL
Intervention: Mandibular banded premolar anchorage (group A)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Mandibular banded premolar-molar anchorage (group B)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Mandibular cast splint anchorage (group D)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cast splint anchorage in Class II:1 and Class II:2 cases
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: All three anchorage forms
Number of subjects: 87
Study: 11960019

Group type: EXPERIMENTAL
Intervention: Biological motion stimulus based on a limited lifetime technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tasks involving the discrimination of walking direction or the coherence of a walking figure
Number of subjects: 0
Study: 10618885

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Factors influencing mixed/formula feeding
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Antenatal plan for exclusive breast-feeding
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding in hospital
Number of subjects: 221
Study: 7790785

Group type: EXPERIMENTAL
Intervention: Single, unilateral 'diversified,' high velocity, low amplitude, rotatory thrust technique
Number of subjects: 50
Study: 2089969

Group type: EXPERIMENTAL
Intervention: Hydrogel-coated catheter (H catheter)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Silicone-coated catheter (S catheter)
Number of subjects: 266
Study: 10239544

Group type: EXPERIMENTAL
Intervention: Pro-abortion script transcription
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attitude-congruent script transcription
Number of subjects: 0
Study: 31291863

Group type: EXPERIMENTAL
Intervention: Surgical treatment (group 2)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conservative treatment (group 1)
Number of subjects: 54
Study: 29040268

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (goal systolic pressure < 120 mm Hg)
Number of subjects: 14067
Study: 25381189

Group type: EXPERIMENTAL
Intervention: Reiki therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Companionship
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study: 23563218

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (supportive therapy)
Number of subjects: 23
Study: 21440734

Group type: EXPERIMENTAL
Intervention: Low-dose rabbit antithymocyte globulin (LoD-rATG, 3-5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard doses of rabbit antithymocyte globulin (7-10 mg/kg)
Number of subjects: 0
Study: 19627671

Group type: EXPERIMENTAL
Intervention: Wand computer controlled local analgesia (LA) system
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional LA technique
Number of subjects: 38
Study: 16909140

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus irinotecan (IG) - 300 mg m(‐2) on day 8, gemcitabine on days 1 and 8, repeated every 3 weeks.
Number of subjects: 145

Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (G) - 900 mg m(‐2) on days 1, 8, and 15 every 4 weeks.
Number of subjects: 145
Study: 15294399

Group type: EXPERIMENTAL
Intervention: Endovascular cooling to a target temperature of 33 degrees C for 24 hours using the CoolGard System and Icy catheter.
Number of subjects: 13
Study: 11426345

Group type: EXPERIMENTAL
Intervention: Polypharmacy cream (testosterone 0.8%, isosorbide dinitrate 0.5%, co‐dergocrine mesylate 0.06%)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Testosterone cream (0.8%)
Number of subjects: 42
Study: 10965083

Group type: EXPERIMENTAL
Intervention: Nitrolingual-Spray
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nitroglycerin (NTG) tablets
Number of subjects: 28
Study: 8981709

Group type: EXPERIMENTAL
Intervention: Combined temporal corneal phacoemulsification and superior trabeculectomy with low-dose 5-FU
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trabeculectomy alone with low-dose 5-FU
Number of subjects: 40
Study: 1290475

Group type: EXPERIMENTAL
Intervention: 4 g of oral enterically coated 4‐aminosalicylic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6365490

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30360762

Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26531051

Group type: EXPERIMENTAL
Intervention: Topical natamycin
Number of subjects: 323

Group type: COMPARATOR
Intervention: Topical voriconazole
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Topical natamycin or voriconazole (corrected for treatment arm)
Number of subjects: 323
Study: 24523562

Group type: EXPERIMENTAL
Intervention: D1-like receptor activation with l-DOPA (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D1-like receptor activation with l-DOPA (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D1-like receptor activation with l-DOPA (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 0
Study: 22783919

Group type: EXPERIMENTAL
Intervention: Mesalamine (Asacol®) 1.6 gm b.i.d. for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 20
Study: 20727209

Group type: EXPERIMENTAL
Intervention: Nordic Walking
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no exercise intervention)
Number of subjects: 60
Study: 17438710

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy and radiotherapy
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Socio-economic factors (educational level, matrimonial status, presence of under-age children)
Number of subjects: 222
Study: 16239090

Group type: EXPERIMENTAL
Intervention: Extended-release clarithromycin (CLA-ER) 1000 mg once a day for 5 days
Number of subjects: 362

Group type: COMPARATOR
Intervention: Telithromycin (TELI) 800 mg once a day for 5 days
Number of subjects: 362
Study: 11877352

Group type: EXPERIMENTAL
Intervention: Glanzmann thrombasthenia patients
Number of subjects: 7

Group type: COMPARATOR
Intervention: Measurement of intima-media thickness
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Patients lacking both alpha(IIb)beta(3) and alpha(v)beta(3) complexes
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Patients lacking only alpha(IIb)beta(3)
Number of subjects: 7
Study: 10223677

Group type: EXPERIMENTAL
Intervention: Indirect therapy (group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Direct with indirect therapy (group 3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (control group 1)
Number of subjects: 45
Study: 7602445

Group type: EXPERIMENTAL
Intervention: Therapeutic Community (TC)
Number of subjects: 723

Group type: COMPARATOR
Intervention: Community Residence (CR)
Number of subjects: 723
Study: 2366172

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen with codeine
Number of subjects: 0
Study: 30590610

Group type: EXPERIMENTAL
Intervention: Male flocks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Female flocks
Number of subjects: 14
Study: 30390620

Group type: EXPERIMENTAL
Intervention: Usual care plus Tai Chi intervention for 20 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 150
Study: 27929319

Group type: EXPERIMENTAL
Intervention: Psychomotor intervention program (PIP); activities targeting body awareness, body concepts, space concepts, and time concepts; conducted three times a week for 10 weeks.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Regular rehabilitation center educational program (control group); no PIP intervention; same duration as experimental group.
Number of subjects: 28
Study: 24439830

Group type: EXPERIMENTAL
Intervention: Olanzapine+Sertraline
Number of subjects: 259

Group type: COMPARATOR
Intervention: Olanzapine+Placebo
Number of subjects: 259
Study: 22366535

Group type: EXPERIMENTAL
Intervention: STN‐DBS alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: l‐dopa alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: STN‐DBS plus l‐dopa
Number of subjects: 16

Group type: COMPARATOR
Intervention: Without STN‐DBS and without l‐dopa
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Reflex blinking (STN‐DBS and l‐dopa)
Number of subjects: 16
Study: 20151785

Group type: EXPERIMENTAL
Intervention: BTX‐A‐1 (30 units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BTX‐A‐2 (256 units total)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computerized photographic numerical assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BTX‐A‐2 (3:1 ratio to BTX‐A‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BTX‐A‐1 and BTX‐A‐2
Number of subjects: 0
Study: 19022007

Group type: EXPERIMENTAL
Intervention: Prophylactic low-energy shock wave therapy (SWT) applied to the site of vein harvesting after wound closure (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 100
Study: 15800098

Group type: EXPERIMENTAL
Intervention: Peer + clinic intervention (peer education supplemented by individual risk reduction counselling by a clinician)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Peer only intervention (condom promotion by peer educators only)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Peer + clinic intervention
Number of subjects: 1000
Study: 12185103

Group type: EXPERIMENTAL
Intervention: CPA‐5‐100 (5 mg/day CPA + 100 mg/week TE)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CPA‐5‐200 (5 mg/day CPA + 200 mg/week TE)
Number of subjects: 18

Group type: COMPARATOR
Intervention: CPA‐5‐100
Number of subjects: 18

Group type: COMPARATOR
Intervention: CPA‐5‐200
Number of subjects: 18
Study: 10230181

Group type: EXPERIMENTAL
Intervention: Stimulant medications
Number of subjects: 0
Study: 8694673

Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Valaciclovir 1000 mg
Number of subjects: 987

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 987
Study: 1992688

Group type: EXPERIMENTAL
Intervention: Iodide salt administered to group A (n = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group B (n = 18)
Number of subjects: 35
Study: 6352208

Group type: EXPERIMENTAL
Intervention: Inorganic Cr trichloride
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Brewer's yeast containing GTF
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Brewer's yeast extract without GTF
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31763315

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 30
Study: 27513191

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 25633319

Group type: EXPERIMENTAL
Intervention: Pleasant odor (rose)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Unpleasant odor (leather)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No odor exposure
Number of subjects: 62
Study: 25078977

Group type: EXPERIMENTAL
Intervention: Pregabalin controlled-release (CR) 82.5, 165, 330 or 660 mg/day administered once daily (QD)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pregabalin controlled-release (CR) two-tablet dose
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pregabalin immediate-release (IR) 75, 150, 300 or 600 mg/day administered either twice (BID) or three times (TID) a day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pregabalin controlled-release (CR)
Number of subjects: 84
Study: 21297404

Group type: EXPERIMENTAL
Intervention: Multimedia Enhanced Web site
Number of subjects: 34

Group type: COMPARATOR
Intervention: Basic Web site
Number of subjects: 34
Study: 19321400

Group type: EXPERIMENTAL
Intervention: Bladder pressure measurement (BP) using 50 mL of sterile saline instilled into the bladder, measured in the supine position.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no acute abdominal complaints).
Number of subjects: 75
Study: 17257473

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (5- to 10-mg increments every 12 h, every 3-7 days)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 15302288

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/day
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 11599506

Group type: EXPERIMENTAL
Intervention: HMB in standard encapsulation (SH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HMB in time release capsule (TRH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study: 9543145

Group type: EXPERIMENTAL
Intervention: sICAM-1 serum levels in GD patients developing active inflammatory ophthalmopathy (group 1)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: sICAM-1 serum levels in GD patients developing ophthalmopathy without clinical retroorbital inflammation (group 1)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: sICAM-1 serum levels in GD patients not developing ophthalmopathy (group 2)
Number of subjects: 103

Group type: COMPARATOR
Intervention: sICAM-1 serum levels in both groups compared to healthy controls
Number of subjects: 103
Study: 8303754

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate at 0.6 mg/kg per day
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate at 2.0 mg/kg per day
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate at 6.0 mg/kg per day
Number of subjects: 111

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: All doses of Tirilazad
Number of subjects: 111
Study: 2592475

Group type: EXPERIMENTAL
Intervention: Standard instructions 'not true' for the CBCL 0 category
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified instructions 'never or not true' for the CBCL 0 category
Number of subjects: 0
Study: 29772855

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 48
Study: 26595359

Group type: EXPERIMENTAL
Intervention: Low-fat dairy (LFD)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Carbohydrate-based control (CNT)
Number of subjects: 37
Study: 25652120

Group type: EXPERIMENTAL
Intervention: Kato-Katz technique
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Quality control of Kato-Katz technique
Number of subjects: 1445
Study: 23652908

Group type: EXPERIMENTAL
Intervention: tretinoin plus topical corticosteroids
Number of subjects: 50

Group type: COMPARATOR
Intervention: vehicle plus topical corticosteroid
Number of subjects: 50
Study: 21910803

Group type: EXPERIMENTAL
Intervention: Anti-TNF-α treatment
Number of subjects: 40
Study: 17561259

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5%
Number of subjects: 122

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 122

Group type: COMPARATOR
Intervention: Normal group (no treatment)
Number of subjects: 122
Study: 16055455

Group type: EXPERIMENTAL
Intervention: NSAID (diclofenac)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Non-NSAID (paracetamol and codeine)
Number of subjects: 74
Study: 12532174

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg s.c./24 h
Number of subjects: 7344

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 7344

Group type: COMPARATOR
Intervention: Fondaparinux s.c.
Number of subjects: 7344
Study: 10415058

Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal polyps (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyp tissue fluid
Number of subjects: 0
Study: 7480564

Group type: EXPERIMENTAL
Intervention: High dose of RS 15385
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low dose of RS 15385
Number of subjects: 36
Study: 2257249

Group type: COMPARATOR
Intervention: Estrogen treatment for 1 year
Number of subjects: 38

Group type: COMPARATOR
Intervention: Estro-progestative treatment for 1 year
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conjugated estrogens treatment for 6 months post-oophorectomy
Number of subjects: 38
Study: 7224204

Group type: EXPERIMENTAL
Intervention: Filtered anesthesia circuits
Number of subjects: 520

Group type: COMPARATOR
Intervention: Nonfiltered anesthesia circuits
Number of subjects: 520
Study: 30503169

Group type: EXPERIMENTAL
Intervention: Cognitive measures related to memory and attention
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Sample size calculations for randomized controlled trials
Number of subjects: 312
Study: 28279777

Group type: EXPERIMENTAL
Intervention: Sutureless repair
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sutured repair
Number of subjects: 39

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 39
Study: 26027613

Group type: EXPERIMENTAL
Intervention: Targeted multifaceted quality improvement intervention
Number of subjects: 4800

Group type: COMPARATOR
Intervention: Routine standard of care (control group)
Number of subjects: 4800
Study: 24137971

Group type: EXPERIMENTAL
Intervention: Ascoril (combined broncholytic and expectorant drug)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ambroxol (mucolytic agent)
Number of subjects: 60
Study: 21849822

Group type: EXPERIMENTAL
Intervention: Electrocardiogram interpretation by reader 1 (blinded to troponin)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Electrocardiogram interpretation by reader 2 (blinded to troponin)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Electrocardiogram interpretation (reader 1) for specific signs of ischemia
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Electrocardiogram interpretation (reader 2) for specific signs of ischemia
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Inter-rater agreement for ischemia (blinded to troponin)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Inter-rater agreement for ischemia (unblinded to troponin)
Number of subjects: 121
Study: 20193328

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of pirarubicin (THP) at 1 hour before TUR-BT (30 mg/50 ml, 0.5 hours)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of pirarubicin (THP) at 24 hours before TUR-BT (30 mg/50 ml, 0.5 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group receiving TUR-BT only
Number of subjects: 40
Study: 17426207

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (400 mug/d) for 12 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (12 subjects)
Number of subjects: 30
Study: 15291681

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 20